SciSparc (SPRC) EBT (2016 - 2022)

SciSparc (SPRC) posted EBT of -$359000.0 for Q4 2022, down 113.14% sequentially from $2.7 million in Q3 2022.

SciSparc (SPRC) EBT (2016 - 2022) Analysis & Trends

SciSparc has reported EBT for 5 years, with the latest figure at -$359000.0 in Q4 2022.

Quarterly EBT changed N/A year-over-year to -$359000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $4.4 million (changed N/A YoY) and the FY2025 annual result came in at -$12.6 million, down 67.83% from the prior year.
EBT slipped to -$359000.0 in Q4 2022 per SPRC's latest filing, from $2.7 million in the prior quarter.
Over five years, EBT peaked at $2.7 million in Q3 2022 and troughed at -$12.3 million in Q4 2018.
A 3-year average of -$1.0 million and a median of $140500.0 in 2018 frame the typical range for EBT.
The sharpest annual moves came in 2018 and 2019: EBT slumped 79.48% in 2018, then jumped 2104.76% in 2019.
Over 3 years, EBT stood at -$12.3 million in 2018, then surged by 101.6% to $197000.0 in 2019, then plunged by 282.23% to -$359000.0 in 2022.
According to Business Quant data, EBT over the past three periods registered -$359000.0, $2.7 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	1.39 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.53 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	541.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-767.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	312.46 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	177.81 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-11.37 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	81.49 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-264.70 Mn
10	SciSparc	836,385.99	836,385.99	-	-

Download Data